

Hong Kong Exchanges and Clearing Limited and The Stock Exchange of Hong Kong Limited take no responsibility for the contents of this announcement, make no representation as to its accuracy or completeness and expressly disclaim any liability whatsoever for any loss howsoever arising from or in reliance upon the whole or any part of the contents of this announcement.



北京市春立正達醫療器械股份有限公司

Beijing Chunlizhengda Medical Instruments Co., Ltd.*

(A joint stock limited company incorporated in the People's Republic of China with limited liability)

(Stock Code: 1858)

2025 FIRST QUARTERLY REPORT

This announcement is made by Beijing Chunlizhengda Medical Instruments Co., Ltd.* (the “**Company**”, together with its subsidiaries, the “**Group**”) pursuant to Rules 13.09(2) and 13.10B of the Rules Governing the Listing of Securities on The Stock Exchange of Hong Kong Limited and Part XIVA of the Securities and Futures Ordinance (Cap. 571 of the Laws of Hong Kong) to provide shareholders of the Company and the public with the updated financial information of the Company. This announcement is also published on the website of the Shanghai Stock Exchange simultaneously.

The unaudited results (the “**First Quarterly Report**”) of the Group for the three months ended 31 March 2025 are provided. The financial information contained in the First Quarterly Report was prepared in accordance with the Chinese Accounting Standards for Business Enterprises (“**CASs**”), and consists accounting data which has not been audited. Potential investors and shareholders of the Company are advised to pay attention to the underlying investment risks.

The First Quarterly Report is written in both Chinese and English. In the case of any discrepancies, the Chinese version of the First Quarterly Report shall prevail.

By order of the Board

Beijing Chunlizhengda Medical Instruments Co., Ltd.*

Shi Wenling

Chairman

Beijing, the PRC, 29 April 2025

As at the date of this announcement, the executive directors of the Company are Ms. Shi Wenling, Mr. Shi Chunbao, Ms. Yue Shujun and Mr. Xie Feng Bao; the non-executive director of the Company is Mr. Wang Xin; and the independent non-executive directors of the Company are Ms. Xu Hong, Mr. Wong Tak Shing and Mr. Weng Jie.

* *For identification purposes only*

Securities Code: 688236

Stock Short Name: Chunli Medical

Beijing Chunlizhengda Medical Instruments
Co., Ltd.*
2025 First Quarterly Report

The Board of Directors of the Company and all Directors undertake that this announcement contains no false record, misleading statement or material omission, and assume legal responsibility for the truthfulness, accuracy and completeness of its contents in accordance with law.

Important Notice

The Board of Directors of the Company, the Board of Supervisors, the Directors, Supervisors, senior management warrant that the content of this quarterly report is true, accurate and complete and contains no false record, misleading statement or material omission, and jointly and severally assume legal responsibility for the content of this report.

The person in charge of the Company, the person in charge for accounting affairs of the Company and the person in charge of the accounting department (financial controller) warrant the truthfulness, accuracy and completeness of the financial information contained in this quarterly report.

Whether the financial statements for the first quarter are audited?

☐Yes ☒No

1. Key financial data

Key accounting data and financial indicators

Unit: Yuan Currency: RMB

Item	Current Reporting Period	Corresponding period of last year	Percentage change of the Current Reporting Period as compared to the corresponding period of last year (%)

Revenue	229,843,941.53	221,850,180.79	3.60
Net profit attributable to the shareholders of the listed company	58,071,117.89	55,199,616.28	5.20
Net profit attributable to the shareholders of the listed company after deducting non-recurring profit or loss	52,698,123.38	48,882,462.10	7.81
Net cash flows generated from operating activities	-75,343,585.60	-129,613,339.07	N/A
Basic earnings per share (RMB/share)	0.15	0.14	7.14
Diluted earnings per share (RMB/share)	0.15	0.14	7.14
Weighted average RONA (%)	2.04	1.90	Increase by 0.14 percentage point
Total investments in research and development	26,897,460.32	34,991,868.71	-23.13
Percentage of research and development investment to revenue (%)	11.70	15.77	Decrease by 4.07 percentage points
	At the end of the Current Reporting Period	At the end of last year	Percentage change at the end of the Current Reporting Period as compared to the end of last year (%)
Total assets	3,473,532,404.39	3,465,734,982.98	0.22
Owners' equity attributable to the	2,877,973,401.17	2,819,902,283.28	2.06

shareholders of the listed company			
------------------------------------	--	--	--

Non-recurring profit or loss items and amounts

☒Applicable ☐Non applicable

Unit: Yuan Currency: RMB

Non-recurring gain or loss item	Amount for the Reporting Period	Description
Gain and loss from disposal of non-current assets, including write-off of provision for asset impairment	-15,716.81	
Government grants included in profit or loss for the current period, excluding government grants that are closely related to the normal operation of the Company, complying with the requirements of national policy, entitled as per the standard established, and those that have continuous effect to the profit and loss of the Company	1,038,221.69	
Except for effective hedging business conducted in the ordinary course of business of the Company, gain or loss arising from change in fair value of financial assets held by and financial liabilities arising from non-financial enterprises, and gain or loss arising from disposal of financial assets and financial liabilities	4,821,333.70	
Capital utilization fee received from non-financial enterprises included in current gain or loss		
Gain or loss on entrusted investments or assets under management		
Gain or loss on entrusted loans		
Loss on assets due to force majeure events, such as natural disasters		
Reversal of the impairment provision for receivables under independent impairment test		
Investments of subsidiaries, associates and joint ventures in which the investment cost was less than the profit at fair value of		

identifiable net assets of the investees at the time of acquisition		
Net gain or loss of subsidiaries for the current period from the beginning of the period to the date of consolidation arising from business consolidation under common control		
Gain or loss on exchange of non-monetary assets		
Gain or loss on debt restructuring		
One-off expenses incurred by enterprises due to the discontinuity of relevant business activities, such as staff resettlement expenses		
One-off effect on current profit or loss due to the adjustments to laws and regulations on tax and accounting		
One-off share-based payment expenses recognised due to cancellation and modification of share incentive scheme		
Gain or loss arising from changes in the fair value of employee benefits for cash-settled share-based payments, payable after the vesting date		
Gain or loss arising from changes in fair value of investment properties under fair value method on subsequent measurement		
Gain on transactions at unfair trading prices		
Gain or loss from other contingencies which are not related to the Company's normal operations		
Custody fee income from custody operations		
Other non-operating income and expenses other than aforesaid items		
Other gain or loss items within the definition of non-recurring profit or loss	482,446.01	
Less: Effect of income tax	944,347.38	
Impact of minority interests (after tax)	8,942.70	
Total	5,372,994.51	

Reasons should be given for the Company defining the non-recurring gain or loss items with

significant amount not set out in the Explanatory Announcement No. 1 on Information Disclosure by Companies Offering Securities to the Public – Non-recurring Gain or Loss along with non-recurring gain or loss items set out in the Explanatory Announcement No. 1 on Information Disclosure by Companies Offering Securities to the Public – Non-recurring Gain or Loss as recurring gain or loss items.

√Applicable ☐Not applicable

Unit: Yuan Currency: RMB

Item	Amount involved	Reason(s)
Additional deduction of value-added tax for advanced manufacturing industry	244,544.67	Continuous impact on gains or losses of the Company
Government grants related to assets	1,145,570.24	Continuous impact on gains or losses of the Company

Description and reasons for the changes in key accounting data and financial indicators

√Applicable ☐Not applicable

Item	Change percentage (%)	Main reason(s)
Net cash flows generated from operating activities	N/A	The net cash flows from operating activities of the Company have improved as compared to the corresponding period of last year, mainly due to the Company's reasonable control of operating expenses and enhancement of fund utilisation efficiency during the Reporting Period, resulting in a decrease in cash outflow from operating activities.

2. Information of shareholders

(A) Total number of ordinary shareholders, preferred shareholders with voting rights reinstated, and the shareholding of top ten shareholders

Unit: Share

Total number of ordinary shareholders at the end of the Reporting Period		7,182	Total number of shareholders of preferred shares with voting rights reinstated (if any) at the end of the Reporting Period			0	
Shareholding of top ten shareholders (excluding lending shares through securities financing)							
Name of shareholder	Nature of shareholder	Number of shares held	Share holding percentage (%)	Number of shares held subject to trading restrictions	Number of Shares subject to trading restrictions that include lending shares through securities financing	Shares charged, tagged or frozen	
						Status of shares	Number
Shi Chunbao	Domestic natural person	118,769,747	30.96	113,685,435	113,685,435	None	0
Yue Shujun	Domestic natural person	95,447,900	24.88	95,447,900	95,447,900	None	0

Beijing Panmao Investme nt Manage ment Co., Ltd. — Panmao (Shangha i) Investme nt Center (LLP) (北京盤 茂投資 管理有 限公司 —盤茂 (上 海) 投 資中心 (有限 合夥))	Domest ic non- state owned legal person	17,250,000	4.50	0	0	Unkn own	-
---	--	------------	------	---	---	-------------	---

GF Securities Co., Ltd. (廣發證券股份有限公司) – Zhong Geng Smallcap Share-dividend Value Securities Investment Fund (中庚小盤價值股票型證券投資基金)	Domestic non-state owned legal person	2,870,514	0.75	0	0	Unknown	-
Huang Dong	Domestic natural person	2,533,335	0.66	0	0	Unknown	-

Beijing Panmao Investment Management Co., Ltd. – Panxin (Shanghai) Investment Center (LLP) (北京盤茂投資管理有限公司—盤信(上海)投資中心(有限合夥))	Domestic non-state owned legal person	2,500,000	0.65	0	0	Unknown	-
Hong Kong Securities Clearing Company Limited	Overseas legal person	2,289,060	0.60	0	0	Unknown	-

Huatai Securities (Shanghai) Asset Management Co., Ltd. (華泰證券資管) – Huatai Chunli Medical Family No. 1 the collective asset management plan for the shareholding of staff on Technology Innovation Board (華泰春立醫療家園1號創板員工持股集合資產)	Domestic non-state owned legal person	1,744,782	0.45	0	0	Unknown	-
--	---------------------------------------	-----------	------	---	---	---------	---

管理計 劃)							
Dongfan g Securitie s Co., Ltd. (東 方證券 股份有 限公司) – Zhong Geng Value Vanguar d Stock Securitie s Investme nt Fund (中庚價 值先鋒 股票型 證券投 資基金)	Domest ic non- state owned legal person	1,365,238	0.36	0	0	Unkn own	-

China Securities (中信 建投證券) – China CITIC Bank – China Securities Value Growth Hybrid Collective Asset Management Plan (中 信建投 價值增 長混合 型集合 資產管 理計劃)	Domestic non- state owned legal person	1,360,278	0.35	0	0	Unknown	-
Shareholding of top ten shareholders not subject to trading restrictions (excluding lending shares through securities financing)							
Name of shareholder	Number of tradable shares held not subject to trading restrictions	Share class and number					
		Share class		Number			

Beijing Panmao Investment Management Co., Ltd. – Panmao (Shanghai) Investment Center (LLP) (北京盤茂投資管理有限公司—盤茂(上海)投資中心(有限合夥))	17,250,000	RMB-denominated ordinary shares	17,250,000
GF Securities Co., Ltd. (廣發證券股份有限公司) – Zhong Geng Smallcap Share-dividend Value Securities Investment Fund (中庚小盤價值股票型證券投資基金)	2,870,514	RMB-denominated ordinary shares	2,870,514
Huang Dong	2,533,335	RMB-denominated ordinary shares	2,533,335

Beijing Panmao Investment Management Co., Ltd. – Panxin (Shanghai) Investment Center (LLP) (北京盤茂投資管理有限公司—盤信(上海)投資中心(有限合夥))	2,500,000	RMB-denominated ordinary shares	2,500,000
Hong Kong Securities Clearing Company Limited	2,289,060	RMB-denominated ordinary shares	2,289,060
Huatai Securities (Shanghai) Asset Management Co., Ltd. – Huatai Chunli Medical Family No. 1 the collective asset management plan for the shareholding of staff on Technology Innovation Board (華泰春立醫療家園1號科創板員工持股集合資產管理計劃)	1,744,782	RMB-denominated ordinary shares	1,744,782

Dongfang Securities Co., Ltd. (東方證券股份有限公司) – Zhong Geng Value Vanguard Stock Securities Investment Fund (中庚價值先鋒股票型證券投資基金)	1,365,238	RMB-denominated ordinary shares	1,365,238
China Securities (中信建投證券) – China CITIC Bank – China Securities Value Growth Hybrid Collective Asset Management Plan (中信建投價值增長混合型集合資產管理計劃)	1,360,278	RMB-denominated ordinary shares	1,360,278
Agricultural Bank of China Limited – Ping An Low Carbon Economy Hybrid Securities Investment Fund (平安低碳經濟混合型證券投資基金)	1,000,000	RMB-denominated ordinary shares	1,000,000

Securities Account Designated for the Repurchase of Beijing Chunlizhengda Medical Instruments Co., Ltd.	868,145	RMB-denominated ordinary shares	868,145
Description of connected relationship or acting in concert of the above shareholders	<p>1. As of the date of this report, Shi Chunbao and Yue Shujun are couple while Panmao and Panxin are the same controlling party. Apart from the above, the Company does not receive any statement from the top ten shareholders regarding the existence of connected relationship or agreement of acting-in concert;</p> <p>2. The Company is not aware of the existence of connected relationship among shareholders of tradable shares, or if they are the concerted parties under the stipulation of Measures for the Administration of Disclosure of Shareholder Equity Changes of Listed Companies.</p>		
Description on participation in margin financing and securities lending and lending shares for securities financing by top ten shareholders and top ten shareholders not subject to trading restrictions (if any)	None		

As of the end of the Reporting Period, the total number of ordinary shareholders of the Company amounted to 7,182, of which 7,167 holders of A Shares and 15 holders of H Shares;

Lending of shares by shareholders involved in the securities financing business holding more than 5% of the shares, top 10 shareholders and top 10 shareholders of tradable shares not subject to trading restrictions

☐ Applicable ☒ Not applicable

The changes of the top 10 shareholders and the top 10 shareholders of tradable shares not subject to trading restrictions resulted from lending/repayment for securities financing compared with the previous period

☐ Applicable ☒ Not applicable

3. Other notice

Other important information related to the operational conditions of the Company during the Reporting Period which requires the attention of the investors

☐ Applicable ☒ Not applicable

4. Quarterly financial statements

Type of auditor's opinion

☐ Applicable ☒ Not applicable

Financial statements

CONSOLIDATED BALANCE SHEET

31 March 2025

Presenting unit: Beijing Chunlizhengda Medical Instruments Co., Ltd.

Unit: Yuan Currency: RMB Type of audit: Unaudited

Items	31 March 2025	31 December 2024
Current assets:		
Monetary funds	1,797,127,279.71	1,139,778,517.24
Settlement reserve		
Placements with banks and non-bank financial institutions		
Held-for trading financial assets		745,797,775.34
Derivative financial assets		
Notes receivable	189,462,497.00	160,052,600.00
Accounts receivable	267,008,618.03	218,658,632.35
Accounts receivable financing		
Prepayment	14,733,521.15	2,993,330.49
Premium receivable		
Reinsurance premium receivables		
Reserves for reinsurance contract receivables		
Other receivables	307,752.96	177,919.45
Including: Interests receivable		
Dividends receivable		
Financial assets purchased under agreements to resell		
Inventories	561,223,487.42	550,842,677.89
Including: Data resources		
Contract assets		
Assets held for-sale		
Non-current assets due within one year		
Other current assets	19,178,817.03	22,179,673.24
Total current assets	2,849,041,973.30	2,840,481,126.00
Non-current assets:		
Loans and advances		
Debt investments		

Other debt investments		
Long-term receivables		
Long-term equity investments		
Other investments in equity instruments		
Other non-current financial assets		
Investment property		
Fixed assets	306,852,546.27	311,008,174.74
Construction in progress	157,013,841.57	156,777,773.93
Productive biological assets		
Oil & gas assets		
Right-of-use assets	849,854.51	1,017,028.37
Intangible assets	126,594,895.15	127,569,991.24
Including: Data resources		
Development expenditures		
Including: Data resources		
Goodwill		
Long-term prepayments		
Deferred income tax assets	26,803,568.01	26,113,029.08
Other non-current assets	6,375,725.58	2,767,859.62
Total non-current assets	624,490,431.09	625,253,856.98
Total assets	3,473,532,404.39	3,465,734,982.98
Current liabilities:		
Short-term borrowings		
Borrowings from central banks		
Placements from banks and non-bank financial institutions		
Held-for trading financial liabilities		
Derivative financial liabilities		
Notes payable		
Accounts payable	198,903,468.21	227,845,174.60
Advances received		
Contract liabilities	116,318,303.36	128,563,190.58
Financial assets sold under repurchase agreement		
Deposits and placements from peers		

Brokerage for trading securities		
Brokerage for underwriting securities		
Employee Remuneration payable	50,495,065.55	52,272,626.41
Taxes payable	9,138,600.75	6,656,073.81
Other payables	64,852,803.63	69,459,231.16
Including: Interests payable		
Dividends payable		
Handling fee and commission payables		
Reinsurance premium payables		
Liabilities held-for-sale		
Non-current liabilities due within one year	689,019.32	682,121.00
Other current liabilities	56,801,268.33	61,266,897.36
Total current liabilities	497,198,529.15	546,745,314.92
Non-current liabilities:		
Reserves for insurance contracts		
Long-term borrowings		
Bonds payable		
Including: Preferred shares		
Perpetual bonds		
Lease liabilities	149,736.77	184,315.07
Long-term payables		
Long-term employee remuneration payable		
Estimated liabilities		
Deferred gains	85,822,589.30	86,749,559.54
Deferred income tax liabilities	10,986,834.67	10,711,656.65
Other non-current liabilities		
Total non-current liabilities	96,959,160.74	97,645,531.26
Total liabilities	594,157,689.89	644,390,846.18
Owners' equity (or shareholders' equity):		
Paid-in capital (or share capital)	383,568,500.00	383,568,500.00

Other equity instruments		
Including: Preferred shares		
Perpetual bonds		
Capital reserve	1,044,799,419.83	1,044,799,419.83
Less: Treasury shares	12,018,864.19	12,018,864.19
Other comprehensive income		
Specific reserve		
Surplus reserve	201,343,486.94	195,115,661.94
General reserve		
Undistributed profits	1,260,280,858.59	1,208,437,565.70
Total equity attributable to owners (or equity attributable to shareholders) of the parent company	2,877,973,401.17	2,819,902,283.28
Minority interests	1,401,313.33	1,441,853.52
Total owners' equity (or shareholders' equity)	2,879,374,714.50	2,821,344,136.80
Total liabilities and owners' equity (or shareholders' equity)	3,473,532,404.39	3,465,734,982.98

Person in charge of the Company: Shi Wenling; Person in charge for accounting affairs of the Company: Li Yumei; Person in charge of the accounting department: Li Yumei

Consolidated income statement

January to March 2025

Prepared by: Beijing Chunlizhengda Medical Instruments Co., Ltd.*

Unit: Yuan Currency: RMB Type of audit: Unaudited

Items	First quarter of 2025	First quarter of 2024
1. Total operating revenue	229,843,941.53	221,850,180.79
Including: Operating revenue	229,843,941.53	221,850,180.79
Interest income		
Premiums gained		
Income from handling fee and commission		
2. Total operating cost	163,972,970.30	164,450,441.62
Including: Operating cost	76,572,465.53	58,041,719.59
Interest expense		
Handling fee and commission expense		
Surrender value		

Net amount of compensation payout		
Net amount of insurance contracts reserves withdrawn		
Policy dividend payment		
Reinsurance Expenses		
Taxes and surcharge	1,960,604.51	1,832,378.18
Selling expenses	46,121,370.37	63,145,976.61
Administrative expenses	16,587,602.35	7,522,645.72
Research and development expenses	26,897,460.32	34,991,868.71
Financial expenses	-4,166,532.78	-1,084,147.19
Including: Interest expenses		
Interest income	4,176,613.37	1,263,505.11
Add: Other gains	2,183,975.41	2,736,455.16
Investment income (losses are presented as “-”)	3,217,026.86	3,286,525.21
Including: Investment income from associates and joint ventures		
Gains from derecognition of financial assets measured at amortised cost		
Foreign exchange gains (losses are presented as “-”)		
Net profit on hedging exposure (losses are presented as “-”)		
Gains on changes of fair value (losses are presented as “-”)	1,604,306.84	1,380,799.84
Loss on credit impairment (losses are presented as “-”)	-7,583,337.28	-5,451,806.83
Loss on asset impairment (losses are presented as “-”)	-790,286.65	-26,245.26
Gains on disposal of assets (losses are presented as “-”)	-15,716.81	
3. Operating profit (losses are presented as “-”)	64,486,939.60	59,325,467.29
Add: Non-operating income	0.04	856,134.36
Less: Non-operating expenses		17,033.00
4. Gross profit (total losses are presented as “-”)	64,486,939.64	60,164,568.65
Less: Income tax expenses	6,456,361.94	5,057,505.44

5. Net profit (net losses are presented as “-”)	58,030,577.70	55,107,063.21
(A) Classified by continuity of operation		
1. Net profit for continuing operation (net losses are presented as “-”)	58,030,577.70	55,107,063.21
2. Net profit for ceased operation (net losses are presented as “-”)		
(B) Classified by ownership		
1. Net profit attributable to the shareholders of the parent company (net losses are presented as “-”)	58,071,117.89	55,199,616.28
2. Non-controlling shareholders' profit or loss (net losses are presented as “-”)	-40,540.19	-92,553.07
6. Net other comprehensive income after tax		
(I) Net other comprehensive income after tax attributable to the owners of the parent company		
1. Other comprehensive income that cannot be reclassified into profit or loss		
(1) Changes in remeasurement on defined benefit plan		
(2) Other comprehensive income that cannot be transferred to profit and loss under equity method		
(3) Fair value change on other investments in equity instruments		
(4) Fair value change on credit risk of the enterprise		
2. Other comprehensive income that will be reclassified into profit or loss		
(1) Other comprehensive income that can be transferred to profit and loss under equity method		
(2) Fair value change on other debt investments		
(3) Amounts of financial assets reclassified into other comprehensive income		
(4) Provision on credit impairment on other debt investments		

(5) Reserves of cash flow hedging		
(6) Translation difference on financial statements denominated in foreign currencies		
(7) Others		
(II) Net other comprehensive income after tax attributable to non-controlling shareholders		
7. Total comprehensive income	58,030,577.70	55,107,063.21
(A) Total comprehensive income attributable to the owners of the parent company	58,071,117.89	55,199,616.28
(B) Total comprehensive income attributable to non-controlling shareholders	-40,540.19	-92,553.07
8. Earnings per share:		
(A) Basic earnings per share (RMB/share)	0.15	0.14
(B) Diluted earnings per share (RMB/share)	0.15	0.14

For business combination under common control conducted during the current period, the acquiree achieved a net profit of RMB0.00 before the combination; the acquiree achieved a net profit of RMB0.00 during the previous period.

Person in charge of the Company: Shi Wenling; Person in charge for accounting affairs of the Company: Li Yumei; Person in charge of the accounting department: Li Yumei

Consolidated cash flow statement

January to March 2025

Prepared by: Beijing Chunlizhengda Medical Instruments Co., Ltd.*

Unit: Yuan Currency: RMB Type of audit: Unaudited

Items	First quarter of 2025	First quarter of 2024
1. Cash flows from operating activities:		
Cash receipts from sale of goods and rendering of services	154,928,044.70	211,271,503.82
Net increase in the amounts of deposits from customers and placements from peers		
Net increase in amounts due to central banks		
Net increase in placements from other financial institutions		

Cash received from the premium of original insurance contract		
Net cash received from reinsurance business		
Net increase in policyholder deposits and amount for investment		
Cash received from interest, handling fee and commission		
Net increase in placements from banks and non-bank financial institutions		
Net increase in capital on business repurchased		
Net cash received on securities dealing agency services		
Receipts of tax refund		
Other cash receipts related to operating activities	5,079,610.43	6,154,227.49
Subtotal of cash inflow from operating activities	160,007,655.13	217,425,731.31
Cash payments for goods purchased and services received	118,196,154.09	113,299,416.02
Net increase in loans and advances from customers		
Net increase in amounts deposited in central bank and peers		
Cash payment on compensation payout in original insurance contract		
Net increase in placements with banks and non-bank financial institutions		
Cash payment on interest, handling fee and commission		
Cash payment for policy dividend		
Cash paid to and on behalf of employees	56,582,807.71	93,446,152.89
Taxes paid	10,570,701.96	42,675,687.92

Other cash payments related to operating activities	50,001,576.97	97,617,813.55
Subtotal cash outflow from operating activities	235,351,240.73	347,039,070.38
Net cash flows from operating activities	-75,343,585.60	-129,613,339.07
2. Cash flows from investing activities:		
Cash received from disinvestments	744,000,000.00	831,300,000.00
Cash received from return on investments	6,619,109.04	5,491,333.43
Net cash received from the disposal of fixed assets, intangible assets and other long-term assets		437,732.49
Net cash received from the disposal of subsidiaries and other business units		
Other cash receipts related to investing activities		
Subtotal of cash inflow from investing activities	750,619,109.04	837,229,065.92
Cash paid for acquiring fixed assets, intangible assets and other long-term assets	18,309,973.69	13,500,759.37
Cash payments for investments		740,000,000.00
Net increase in pledged loans		
Net cash payments for acquisitions of subsidiaries and other business units		
Other cash payments related to investing activities		
Subtotal of cash outflow from investing activities	18,309,973.69	753,500,759.37
Net cash flows from investing activities	732,309,135.35	83,728,306.55
3. Cash flows from financing activities:		
Cash received from investments		
Including: Cash received by subsidiaries from non-controlling shareholders' investments		
Cash received from borrowings		
Other cash receipts related to financing activities		

Subtotal of cash inflow from financing activities		
Cash repayment of debts		
Cash paid for distribution of dividends, profits or for interest expenses		
Including: Dividends and profit paid by subsidiaries to non-controlling shareholders		
Other cash payments related to financing activities	35,877.14	
Subtotal of cash outflow from financing activities	35,877.14	
Net cash flows from financing activities	-35,877.14	
4. Effect of foreign exchange rate changes on cash and cash equivalents	87,041.01	-4,213.37
5. Net increase in cash and cash equivalents	657,016,713.62	-45,889,245.89
Add: Opening balance of cash and cash equivalents	1,139,017,650.66	1,266,013,075.67
6. Closing balance of cash and cash equivalents	1,796,034,364.28	1,220,123,829.78

Person in charge of the Company: Shi Wenling; Person in charge for accounting affairs of the Company: Li Yumei; Person in charge of the accounting department: Li Yumei

Adjustments to the financial statements at the beginning of the year of the first implementation due to the first implementation of the new accounting standards or interpretation of accounting standards since 2025

☐Applicable ☒Non applicable

The Board of Directors of Beijing Chunlizhengda Medical Instruments Co., Ltd.*
30 April 2025

* For identification purposes only